UCB's Total Assets for the quarter that ended in Dec. 2025 was €18,158 Mil.
During the past 12 months, UCB's average Total Assets Growth Rate was 0.80% per year.
During the past 3 years, the average Total Assets Growth Rate was 2.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 6.00% per year.
During the past 10 years, the average Total Assets Growth Rate was 6.70% per year.
During the past 13 years, UCB's highest 3-Year average Total Assets Growth Rate was 47.00%. The lowest was -3.40%. And the median was 2.20%.
Total Assets is connected with ROA %. UCB's annualizedROA % for the quarter that ended in Dec. 2025 was 12.26%. Total Assets is also linked to Revenue through Asset Turnover. UCB's Asset Turnover for the quarter that ended in Dec. 2025 was 0.24.
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
UCB's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
UCB Total Assets Related Terms
UCB Total Assets Historical Data
* Premium members only.
The historical data trend for UCB's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
UCB's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UCB (STU:UNC) has a Total Assets of €18,158 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on UCB and its competitors.
Is UCB's Total Assets too high?
UCB's current Total Assets is €18,158 Mil. Overall, UCB has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UCB's Total Assets compare to VRTX and REGN?
UCB's Total Assets of €18,158 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on UCB and its competitors. UCB's current Total Assets is €18,158 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (STU:UNC) is currently considered Modestly Overvalued. The stock's GF Value™ is €211.18, compared to a current price of €250.00 — trading 18.4% above its estimated fair value. The current Total Assets is €18,158 Mil. UCB's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For UCB (STU:UNC), the current Total Assets is €18,158 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UCB (STU:UNC) Overvalued in 2026?
Based on GuruFocus' analysis, UCB stock appears to be overvalued.
The current stock price of €250.00 is trading 18.4% above its estimated GF Value™ of €211.18.
GuruFocus considers UCB to be Modestly Overvalued.
Key valuation signals for STU:UNC:
Total Assets: €18,158 Mil
GF Value™: €211.18 vs. price of €250.00 (18.4% above fair value)
No single metric tells the full story. See the STU:UNC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
89GF Score
Get the complete analysis for STU:UNC
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:UNC has been successfully added to your 
